ArticleBriefings in bioinformatics2025
Accelerate the discovery of genetic variants in mitochondrial diseases with Variant prIOritization using Latent spAce.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Interpreting variants from whole-exome sequencing remains a major challenge, particularly for heterogeneous disorders such as mitochondrial diseases (MDs). To address this, we have developed Variant prIoritizatiOn using Latent spAce (VIOLA), a pipeline designed to help find a diagnosis for complex cases. VIOLA uses a variational autoencoder to embed functional annotations into a low-dimensional space, followed by DBSCAN-based outlier detection to identify potential pathogenic variants. Filtering steps and phenotype integration via HPO terms are then applied. The VIOLA score (Vscore) combines variant outlierness, transcriptomic co-expression data, and MD-specific annotations. Two rankings are derived: the VIOLA rank (all variants) and the ARrank (variants compatible with autosomal recessive inheritance). The VIOLA Aggregated score (VAscore) merges Vscore with Exomiser's pathogenicity score. Applied to 20 patients (four diagnosed), VIOLA reduced the variant list by >99% and ranked causal variants within the top 5 using ARrank, outperforming existing methods. Overall, VIOLA is a patient-specific strategy for variant prioritization, helping to resolve challenging MD cases and uncover novel disease mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.